Literature DB >> 12923721

Nonimmunosuppressive therapy of membranous nephropathy.

Arrigo Schieppati1, Piero Ruggenenti, Annalisa Perna, Giuseppe Remuzzi.   

Abstract

Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923721     DOI: 10.1016/s0270-9295(03)00050-0

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  3 in total

Review 1.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 2.  Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma.

Authors:  Chi Chiu Mok
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

3.  Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness.

Authors:  Claudio Bazzi; Virginia Rizza; Daniela Casellato; Rafid Tofik; Anna-Lena Berg; Maurizio Gallieni; Giuseppe D'Amico; Omran Bakoush
Journal:  BMC Nephrol       Date:  2014-05-08       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.